IL6R and congenital rubella syndrome: Tocilizumab, an antibody that blocks the interleukin 6-receptor (IL-6R) and thus modulates cytokine expression, is applied to treat CRS in CAR-T therapies and in other diseases related to excessive cytokine expression [54].